caa a22 4500 555285359 20200410031630.0 cr unu---uuuuu 190206s2018 xx s 000 0 eng 1932-6203 10.1371/journal.pone.0202950 doi (BORIS)oai:boris.unibe.ch:125209 610 ddc 30148864 pmid Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography [Elektronische Daten] [Christian Zanchin, Kyohei Yamaji, Carolin Rogge, Dorothea Lesche, Thomas Zanchin, Yasushi Ueki, Stephan Windecker, Paul Mohacsi, Lorenz Räber, Vilborg Sigurdardottir] publishedVersion openAccess eu-repo BACKGROUND The purpose of the present study was to assess the short- and long-term progression of cardiac allograft vasculopathy (CAV) using serial 3-vessel quantitative coronary angiography (QCA). METHODS CAV progression was assessed using serial 3-vessel QCA analysis at baseline, 1-year and long-term angiographic follow-up (8.5±3.7 years) after heart transplantation. The change in minimal lumen diameter (MLD) and percent diameter stenosis (%DS) was serially assessed within matched segments. Patients were graded according to the ISHLT-CAV classification and grouped as ISHLT-CAV0 and ISHLT-CAV1-3. The primary endpoint was mean change in MLD and %DS. RESULTS A total of 41 patients and 520 matched segments were available for serial 3-vessel QCA. Overall, MLD decreased non-significantly from baseline to 1-year follow-up and significantly from 1-year to the long-term angiographic follow-up (Δ-0.08mm/year [95%CI -0.11 to -0.05], P<0.001). %DS increased significantly from baseline to 1-year (Δ+0.96%/year [95%CI 0.04 to 1.88], P = 0.041) and from 1-year to long-term angiographic follow-up (Δ+0.61%/year [95%CI 0.33 to 0.88], P<0.001). ISHLT-CAV1-3 at 1 year and at long-term angiographic follow-up was observed in 22% and 61%, respectively. Between baseline and long-term angiographic follow-up, a significant reduction in MLD was observed within both groups without a significant difference in the reduction between the two groups (ISHLT-CAV0: median -0.49mm [IQR -0.54 to -0.43] vs. ISHLT-CAV1-3: median -0.40mm [IQR -0.44 to -0.35], P = 0.4). CONCLUSION The current data suggest that QCA can't predict CAV beyond 1 year, but, QCA affirmed that CAV progresses to a similar extent in patients who do not develop visual CAV during long-term follow-up. Zanchin Christian joint author Yamaji Kyohei joint author Rogge Carolin joint author Lesche Dorothea joint author Zanchin Thomas joint author Ueki Yasushi joint author Windecker Stephan joint author Mohacsi Paul joint author Räber Lorenz joint author Sigurdardottir Vilborg joint author PLoS ONE 13(8), e0202950 1932-6203 https://boris.unibe.ch/125209/1/Progression%20of%20cardiac%20allograft%20vasculopathy%20.pdf text/html WWW-Backlink auf das Repository 1 info:eu-repo/semantics/article boris PeerReviewed boris peerstatus BORIS 856 40 https://boris.unibe.ch/125209/1/Progression%20of%20cardiac%20allograft%20vasculopathy%20.pdf text/html WWW-Backlink auf das Repository BORIS 700 1- Zanchin Christian joint author BORIS 700 1- Yamaji Kyohei joint author BORIS 700 1- Rogge Carolin joint author BORIS 700 1- Lesche Dorothea joint author BORIS 700 1- Zanchin Thomas joint author BORIS 700 1- Ueki Yasushi joint author BORIS 700 1- Windecker Stephan joint author BORIS 700 1- Mohacsi Paul joint author BORIS 700 1- Räber Lorenz joint author BORIS 700 1- Sigurdardottir Vilborg joint author BORIS 773 0- PLoS ONE 13(8), e0202950 1932-6203 BK010053 XK010053 XK010000 BORIS BORIS BORIS info:eu-repo/semantics/article openAccess